Armistice Capital LLC purchased a new stake in Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 272,000 shares of the company’s stock, valued at approximately $255,000. Armistice Capital LLC owned 8.74% of Sonnet BioTherapeutics at the end of the most recent quarter.
Sonnet BioTherapeutics Stock Performance
Shares of Sonnet BioTherapeutics stock opened at $0.73 on Friday. The firm has a 50-day simple moving average of $0.81 and a two-hundred day simple moving average of $1.34. Sonnet BioTherapeutics Holdings, Inc. has a fifty-two week low of $0.62 and a fifty-two week high of $2.97.
Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.06. Sonnet BioTherapeutics had a negative return on equity of 398.45% and a negative net margin of 11,187.19%. On average, equities research analysts forecast that Sonnet BioTherapeutics Holdings, Inc. will post -1.61 earnings per share for the current year.
Analyst Ratings Changes
Get Our Latest Analysis on SONN
Sonnet BioTherapeutics Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
See Also
- Five stocks we like better than Sonnet BioTherapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What to Know About Investing in Penny Stocks
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- The Most Important Warren Buffett Stock for Investors: His Own
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Receive News & Ratings for Sonnet BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonnet BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.